REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

RGNX 10.18.2024

Full Press ReleaseSEC FilingsOur RGNX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
  • 01.13.2025 - AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
  • 12.16.2024 - Ellie Merle

Recent Filings

  • 01.14.2025 - 4/A Statement of changes in beneficial ownership of securities
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

ROCKVILLE, Md.,Oct. 18, 2024/PRNewswire/ --REGENXBIO Inc.(Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at theAmerican Academy of Ophthalmology2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.

New data will be presented as follows:

Title:Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study (abstract 30080148)Presenter:Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research atSierra Eye AssociatesDate/Time:Saturday, October 19, 2024, at11:59 a.m. ET

Encore presentations will be presented as follows:

Title:A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR (abstract 30078795)Presenter:Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research atSierra Eye AssociatesDate/Time:Monday, October 21, 2024, at10:45 a.m. ET

Title:Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD (abstract 30079480)Presenter:Philip P. Storey, M.D.,Austin Retina AssociatesDate/Time:Monday, October 21, 2024, at12:45 p.m. ET

AboutREGENXBIO Inc.REGENXBIOis a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009,REGENXBIOhas pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines.REGENXBIOis advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated withREGENXBIO'sAAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visitwww.regenxbio.com.

Zolgensma®is a registered trademark of Novartis Gene Therapies.

Contacts:Dana CormackCorporate CommunicationsDCORMACK@regenxbio.com

George E. MacDougallInvestor RelationsIR@regenxbio.com

(PRNewsfoto/REGENXBIO Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024-annual-meeting-302280013.html

SOURCEREGENXBIO Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com